Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain

References

• Cronin KA, Lake AJ, Scott S, Sherman RL, Noone A-M, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2018;124(13):2785–2800. doi:10.1002/cncr.31551.
   PubMed Web of Science ®Google Scholar
• Suhy AM, Webb A, Papp AC, Geier EG, Sadee W. Expression and splicing of ABC and SLC transporters in the human blood-brain barrier measured with RNAseq. Eur J Pharm Sci. 2017;103:47–51. doi:10.1016/j.ejps.2017.02.010.
   PubMed Web of Science ®Google Scholar
• Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MAJ, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JHM. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008;7(8):2280–2287. doi:10.1158/1535-7163.MCT-07-2250.
   PubMed Web of Science ®Google Scholar
• Kawamura K, Yamasaki T, Yui J, Hatori A, Konno F, Kumata K, Irie T, Fukumura T, Suzuki K, Kanno I, et al. In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib. Nucl Med Biol. 2009;36(3):239–246. doi:10.1016/j.nucmedbio.2008.12.006.
   PubMed Web of Science ®Google Scholar
• Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lankheet N, Rosing H, Beijnen JH, Schinkel AH. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res. 2009;15(7):2344–2351. doi:10.1158/1078-0432.CCR-08-2253.
   PubMed Web of Science ®Google Scholar
• Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metab Dispos. 2011;39(5):729–735. doi:10.1124/dmd.110.037317.
   PubMed Web of Science ®Google Scholar
• Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm. 2012;9(11):3236–3245. doi:10.1021/mp3003144.
   PubMedGoogle Scholar
• Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH.Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer. 2012;130(1):223–233. doi:10.1002/ijc.26000.
   PubMed Web of Science ®Google Scholar
• Tang SC, Lankheet NA, Poller B, Wagenaar E, Beijnen JH, Schinkel AH. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther. 2012;341(1):164–173. doi:10.1124/jpet.111.186908.
   PubMed Web of Science ®Google Scholar
• Durmus S, Xu N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387. Pharmacol Res. 2013;76:9–16. doi:10.1016/j.phrs.2013.06.009.
   PubMed Web of Science ®Google Scholar
• Lin F, Hoogendijk L, Buil L, Beijnen JH, van Tellingen O. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo. Eur J Cancer. 2013;49(8):2059–2064. doi:10.1016/j.ejca.2012.12.028.
   PubMed Web of Science ®Google Scholar
• Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JHM, Beijnen JH, van Tellingen O. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. Clin Cancer Res. 2013;19(8):2084–2095. doi:10.1158/1078-0432.CCR-12-3105.
   PubMed Web of Science ®Google Scholar
• Marchetti S, Pluim D, van Eijndhoven M, van Tellingen O, Mazzanti R, Beijnen JH, Schellens JHM. Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA. Invest New Drugs. 2013;31(5):1125–1135. doi:10.1007/s10637-013-9923-1.
   PubMed Web of Science ®Google Scholar
• Tang SC, de Vries N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib. J Pharmacol Exp Ther. 2013;346(3):486–494. doi:10.1124/jpet.113.205583.
   PubMed Web of Science ®Google Scholar
• Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. “Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183”. Invest New Drugs. 2014;32(6):1083–1095. doi:10.1007/s10637-014-0143-0.
   PubMed Web of Science ®Google Scholar
• Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharm Res. 2015;32(1):37–46. doi:10.1007/s11095-014-1442-z.
   PubMed Web of Science ®Google Scholar
• Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Brain and testis accumulation of regorafenib is restricted by breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharm Res. 2015;32(7):2205–2216. doi:10.1007/s11095-014-1609-7.
   PubMed Web of Science ®Google Scholar
• Kort A, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Pharmacol Res. 2015;102:200–207. doi:10.1016/j.phrs.2015.09.003.
   PubMed Web of Science ®Google Scholar
• Kort A, van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Brain accumulation of ponatinib and its active metabolite, N-desmethyl ponatinib, is limited by P-Glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Mol Pharm. 2017;14(10):3258–3268. doi:10.1021/acs.molpharmaceut.7b00257.
   PubMedGoogle Scholar
• van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacol Res. 2017;120:43–50. doi:10.1016/j.phrs.2017.01.035.
   PubMed Web of Science ®Google Scholar
• Wang J, Gan C, Sparidans RW, Wagenaar E, van Hoppe S, Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. Pharmacol Res. 2018;129:414–423. doi:10.1016/j.phrs.2017.11.006.
   PubMed Web of Science ®Google Scholar
• Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452–464. doi:10.1038/s41568-018-0005-8.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Hartz AM, Elmquist WF, Bauer B. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des. 2011;17(26):2793–2802. doi:10.2174/138161211797440186.
   PubMed Web of Science ®Google Scholar
• Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014;134(6):1484–1494. doi:10.1002/ijc.v134.6.
   PubMed Web of Science ®Google Scholar
• Foran E, Kwon DY, Nofziger JH, Arnold ES, Hall MD, Fischbeck KH, Burnett BG. CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol Dis. 2016;88:118–124. doi:10.1016/j.nbd.2016.01.008.
   PubMed Web of Science ®Google Scholar
• Joosen MJA, Vester SM, Hamelink J, Klaassen SD, van Den Berg RM. Increasing nerve agent treatment efficacy by P-glycoprotein inhibition. Chem Biol Interact. 2016;259(Pt B):115–121. doi:10.1016/j.cbi.2016.06.012.
   PubMedGoogle Scholar
• Li Y, Woo J, Chmielecki J, Xia CQ, Liao M, Chuang B-C, Yang JJ, Guan MY, Plesescu M, Prakash SR, et al. Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles. Bioorg Med Chem Lett. 2016;26(2):551–555. doi:10.1016/j.bmcl.2015.11.077.
   PubMed Web of Science ®Google Scholar
• Saunders NR, Habgood MD, Mollgard K, Dziegielewska KM. 2016. The biological significance of brain barrier mechanisms: help or hindrance in drug delivery to the central nervous system? F1000 Res. 5. DOI:10.12688/f1000research.
   Google Scholar
• Xu P, Ling ZL, Zhang J, Li Y, Shu N, Zhong Z-Y, Chen Y, Di X-Y, Wang Z-J, Liu L, et al. Unconjugated bilirubin elevation impairs the function and expression of breast cancer resistance protein (BCRP) at the blood-brain barrier in bile duct-ligated rats. Acta Pharmacol Sin. 2016;37(8):1129–1140. doi:10.1038/aps.2016.25.
   PubMed Web of Science ®Google Scholar
• Bauer M, Wulkersdorfer B, Karch R, Philippe C, Jäger W, Stanek J, Wadsak W, Hacker M, Zeitlinger M, Langer O, et al. Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[(11) C]verapamil in elderly vs. young subjects. Br J Clin Pharmacol. 2017;83(9):1991–1999. doi:10.1111/bcp.v83.9.
   PubMed Web of Science ®Google Scholar
• Liu K, Zhu J, Huang Y, Li C, Lu J, Sachar M, Li S, Ma X. Metabolism of KO143, an ABCG2 inhibitor. Drug Metab Pharmacokinet. 2017;32(4):193–200. doi:10.1016/j.dmpk.2017.02.003.
   PubMed Web of Science ®Google Scholar
• de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, van Tellingen O. Improved brain penetration and antitumor efficacy of temozolomide by inhibition of ABCB1 and ABCG2. Neoplasia. 2018;20(7):710–720. doi:10.1016/j.neo.2018.05.001.
   PubMed Web of Science ®Google Scholar
• Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–2872. doi:10.1200/JCO.2004.12.149.
   PubMed Web of Science ®Google Scholar
• Mitri Z, Constantine T, The OR. HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;2012:743193.
   PubMedGoogle Scholar
• Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353(16):1652–1654. doi:10.1056/NEJMp058197.
   PubMed Web of Science ®Google Scholar
• Witzel I, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Fasching PA, et al. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial. Br J Cancer. 2012;107(6):956–960. doi:10.1038/bjc.2012.353.
   PubMed Web of Science ®Google Scholar
• World Cancer Report 2014. World Health Organization;2014.
   Google Scholar
• Novartis. Tykerb tablet package insert; 2017. In:.
   Google Scholar
• Peters S, Zimmermann S. Targeted therapy in NSCLC driven by HER2 insertions. Transl Lung Cancer Res. 2014;3(2):84–88. doi:10.3978/j.issn.2218-6751.2014.02.06.
   PubMedGoogle Scholar
• Polli JW, Humphreys JE, Harmon KA, Castellino S, O’Mara MJ, Olson KL, John-Williams LS, Koch KM, Serabjit-Singh CJ. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008;36(4):695–701. doi:10.1124/dmd.107.018374.
   PubMed Web of Science ®Google Scholar
• Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, Gril B, Hua E, Palmieri D, Polli JW, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res. 2012;29(3):770–781. doi:10.1007/s11095-011-0601-8.
   PubMed Web of Science ®Google Scholar
• Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, Otto V, Castellino S, Demby VE. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016. Drug Metab Dispos. 2009;37(2):439–442. doi:10.1124/dmd.108.024646.
   PubMed Web of Science ®Google Scholar
• Rao MR, Faulkner DJ. Botryllamides E-H, four new tyrosine derivatives from the ascidian Botrylloides tyreum. J Nat Prod. 2004;67(6):1064–1066. doi:10.1021/np0499618.
   PubMed Web of Science ®Google Scholar
• Henrich CJ, Bokesch HR, Dean M, Bates SE, Robey RW, Goncharova EI, Wilson JA, McMahon JB. A high-throughput cell-based assay for inhibitors of ABCG2 activity. J Biomol Screen. 2006;11(2):176–183. doi:10.1177/1087057105284576.
   PubMedGoogle Scholar
• Henrich CJ, Robey RW, Takada K, Bokesch HR, Bates SE, Shukla S, Ambudkar SV, McMahon JB, Gustafson KR. Botryllamides: natural product inhibitors of ABCG2. ACS Chem Biol. 2009;4(8):637–647. doi:10.1021/cb900134c.
   PubMed Web of Science ®Google Scholar
• Takada K, Imamura N, Gustafson KR, Henrich CJ. Synthesis and structure-activity relationship of botryllamides that block the ABCG2 multidrug transporter. Bioorg Med Chem Lett. 2010;20(4):1330–1333. doi:10.1016/j.bmcl.2010.01.016.
   PubMed Web of Science ®Google Scholar
• Bailer AJ. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm. 1988;16(3):303–309. doi:10.1007/BF01062139.
   PubMedGoogle Scholar
• Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem. 2012;19(13):1946–2025. doi:10.2174/092986712800167392.
   PubMed Web of Science ®Google Scholar
• Pena-Solorzano D, Stark SA, Konig B, Sierra CA, Ochoa-Puentes C. ABCG2/BCRP: specific and nonspecific modulators. Med Res Rev. 2017;37(5):987–1050. doi:10.1002/med.2017.37.issue-5.
   PubMed Web of Science ®Google Scholar
• Verheijen RB, Yaqub M, Sawicki E, van Tellingen O, Lammertsma AA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR, Hendrikse NH, et al. Molecular imaging of ABCB1 and ABCG2 inhibition at the human blood-brain barrier using elacridar and (11)C-Erlotinib PET. J Nucl Med. 2018;59(6):973–979. doi:10.2967/jnumed.117.195800.
   PubMed Web of Science ®Google Scholar
• Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res. 2009;26(8):1816–1831. doi:10.1007/s11095-009-9896-0.
   PubMed Web of Science ®Google Scholar
• Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JHM, Koomen G-J, Schinkel AH. 2002. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther. 1(6):417–425.
   PubMed Web of Science ®Google Scholar
• Weidner LD, Zoghbi SS, Lu S, Shukla S, Ambudkar SV, Pike VW, Mulder J, Gottesman MM, Innis RB, Hall MD, et al. The inhibitor Ko143 is not specific for ABCG2. J Pharmacol Exp Ther. 2015;354(3):384–393. doi:10.1124/jpet.115.225482.
   PubMed Web of Science ®Google Scholar
• Thomas Wanek CK, Bankstahl JP, Bankstahl M, Stanek J, Sauberer M, Muller M, Loscher W, Langer O. Inhibition of breast cancer resistance protein at the murine blood-brain barrier by Ko143 studied with [11C]tariquidar and PET. BMC Pharmacol. 2011; 11:A48.
   Google Scholar
• Kelly RJ, Draper D, Chen CC, Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, Otto V, et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res. 2011;17(3):569–580. doi:10.1158/1078-0432.CCR-10-1725.
   PubMed Web of Science ®Google Scholar
• Brandt C, Bethmann K, Gastens AM, Loscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis. 2006;24(1):202–211. doi:10.1016/j.nbd.2006.06.014.
   PubMed Web of Science ®Google Scholar
• Zoghbi SS, Liow JS, Yasuno F, Hong J, Tuan E, Lazarova N, Gladding RL, Pike VW, Innis RB. 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med. 2008;49(4):649–656. doi:10.2967/jnumed.107.047308.
   PubMed Web of Science ®Google Scholar
• Kannan P, Telu S, Shukla S, Ambudkar, S.V., Pike, V.W., Halldin, C., Gottesman, M.M., Innis, R.B, Hall, M.D. The “specific” P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci. 2011;2(2):82–89. doi:10.1021/cn100078a.
   PubMed Web of Science ®Google Scholar